MedTrace Logo

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

NCT07107841 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-12

No results posted yet for this study

Summary

(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365.

Hair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.

Conditions

Interventions

OTHER

Autologous Hair Follicle-Derived Secretome

Hair follicles are plucked, cultured and the product is the resulting cell secretions (secretome) collected from the conditioned media.

OTHER

Placebo Control

The same saline used for diluting the active treatment in will be used as a control.

Sponsors & Collaborators

  • Acorn Biolabs Inc.

    lead INDUSTRY

Principal Investigators

  • Lisa M Campbell, PhD · Acorn Biolabs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-16
Primary Completion
2027-09-15
Completion
2027-09-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07107841 on ClinicalTrials.gov